Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 51 of 51 results for cytokine

  1. Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

    Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.

  2. Baricitinib for treating moderate to severe atopic dermatitis (TA681)

    Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults.

  3. Apremilast for treating active psoriatic arthritis (TA433)

    Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.

  4. TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .

  5. Apremilast for treating moderate to severe plaque psoriasis (TA419)

    Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.

  6. Lyme disease (NG95)

    This guideline covers diagnosing and managing Lyme disease. It aims to raise awareness of when Lyme disease should be suspected and ensure that people have prompt and consistent diagnosis and treatment. It does not cover preventing Lyme disease.